EDS

18 drugs in development·16 companies·1 clinical trial

Drug Pipeline by Phase

Approved(9)

Drug	Company
accelerex sterile wound	REGENEREX PHARMA, INC. (RGPX)
AMNIOCORD	MiMedx Group Inc (MDXG)
lamotrigine	Teva Pharmaceutical Industries Limited (TEVA)
LUMRYZ	Alkermes plc. (ALKS)
pitolisant	Impax Laboratories, LLC (IPXL)
sodium oxybate	Nascent Biotech Inc. (NBIO)
Sunosi	Axsome Therapeutics, Inc. (AXSM)
WAKIX	Harmony Biosciences Holdings, Inc. (HRMY)
xyrem	Jazz Pharmaceuticals plc (JAZZ)

Phase 3(3)

Drug	Company
celiprolol	ZEVRA THERAPEUTICS, INC. (ZVRA)
edsivo	Acer Therapeutics Inc. (ACER)
hbs-301	Harmony Biosciences Holdings, Inc. (HRMY)

Phase 2(1)

Drug	Company
Psilly	AIBOTICS, INC. (AIBT)

Unknown(5)

Drug	Company
AR101	AYTU BIOPHARMA, INC (AYTU)
High-end wine products	China Foods Holdings Ltd. (CFOO)
Mediterranation®	Cosmos Health Inc. (COSM)
Serious Seeds proprietary strains / Collaborative Products	Target Group Inc. (CBDY)
Sky Premium Life (SPL)	Cosmos Health Inc. (COSM)

BioSniper tracks 18 drugs in development for EDS across 16 companies.

There are 1 clinical trial targeting EDS tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.